Sarah N. Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah N. Wright has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Trey Ideker
Program in Bioinformatics and Systems Biology, University of California, San Diego, La Jolla, USA
9 shared publications - Dexter Pratt
Department of Medicine, University of California San Diego, La Jolla, USA
6 shared publications - Akshat Singhal
Department of Computer Science and Engineering, University of California, San Diego, La Jolla, USA
4 shared publications - Chan-Young Ock
Lunit, Seoul, Republic of Korea
4 shared publications - Chang Ho Ahn
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - David Laub
Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA, 92093
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Data from A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
Although genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pretrained on a large corpus of genomic alterations across more than 30,000 tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor’s altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes. Significance:This work describes MutationProjector, a tumor genomic foundation model pretrained on more than 30,000 tumors. It maps mutations to biological states for diagnosis and treatment, achieving state-of-the-art performance in predicting therapy resistance and identifying biomarkers such as KMT2D (sensitivity) and SMARCA4/STK11 coalterations (resistance).
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
Although genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pretrained on a large corpus of genomic alterations across more than 30,000 tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor’s altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes. Significance:This work describes MutationProjector, a tumor genomic foundation model pretrained on more than 30,000 tumors. It maps mutations to biological states for diagnosis and treatment, achieving state-of-the-art performance in predicting therapy resistance and identifying biomarkers such as KMT2D (sensitivity) and SMARCA4/STK11 coalterations (resistance).
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 - S8 from A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
Figure S1 shows mutational heterogeneity of the pre-training dataset. Figure S2 shows detailed model architecture. Figure S3 shows inferring the status of tumor infiltrating lymphocytes. Figure S4 shows the analysis of latent representations. Figure S5 shows the prediction of drug response using clinical biomarkers. Figure S6 shows the prediction of metastasis-related tasks. Figure S7 shows the method for computing feature importance. Figure S8 shows the analysis of high model attention.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 - S8 from A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
Figure S1 shows mutational heterogeneity of the pre-training dataset. Figure S2 shows detailed model architecture. Figure S3 shows inferring the status of tumor infiltrating lymphocytes. Figure S4 shows the analysis of latent representations. Figure S5 shows the prediction of drug response using clinical biomarkers. Figure S6 shows the prediction of metastasis-related tasks. Figure S7 shows the method for computing feature importance. Figure S8 shows the analysis of high model attention.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 - 7 from A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
Table S1 contains the similarities of interaction pairs between networks. Table S2 contains the predictive performance in pretraining tasks. Table S3 contains the feature importance scores for anti-cancer drug response tasks. Table S4 contains the gene alteration frequencies in predicted responders and non-responders in immunotherapy treated lung cancer patients. Table S5 contains gene co-alteration frequencies. Table S6 contains number of patients with tumor infiltrating lymphocyte status information. Table S7 contains the prediction performance of anti-cancer drug response tasks.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 - 7 from A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
Table S1 contains the similarities of interaction pairs between networks. Table S2 contains the predictive performance in pretraining tasks. Table S3 contains the feature importance scores for anti-cancer drug response tasks. Table S4 contains the gene alteration frequencies in predicted responders and non-responders in immunotherapy treated lung cancer patients. Table S5 contains gene co-alteration frequencies. Table S6 contains number of patients with tumor infiltrating lymphocyte status information. Table S7 contains the prediction performance of anti-cancer drug response tasks.
- Open Access
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (10) , 2021-2036
A foundation model of cancer genotype enables precise predictions of therapeutic response
While genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pre-trained from a large corpus of genomic alterations across 30,000+ tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor’s altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (10) , 2021-2036
Open AccessA foundation model of cancer genotype enables precise predictions of therapeutic response
While genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pre-trained from a large corpus of genomic alterations across 30,000+ tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor’s altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes.
- Open Access
- 26 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (8) , 1918-1943
Common and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene selective constraint, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact genes with shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes.
- 26 March 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (8) , 1918-1943
Open AccessCommon and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene selective constraint, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact genes with shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes.
- Open Access
Redefining Parkinson's Disease by Dysregulated Genetic Networks in Distinct Cell Types
Parkinson's disease (PD) is classically linked to dopaminergic neuron loss, but emerging evidence suggests broader cellular involvement. Here we show that PD risk variants converge on distinct molecular networks across specific brain cell types, enabling stratification of patients into six subgroups: dopaminergic, oligodendrocyte progenitor cells (O), excitatory (E), dopaminergic/excitatory, dopaminergic/oligodendrocyte and other. While all subgroups exhibit motor symptoms, the E-group individuals also display more severe non-motor symptoms, including dementia, hyposmia, and REM sleep behavior disorder. The O-group individuals exhibit reduced myelin integrity, as demonstrated by diffusion tensor imaging, implicating NRG6 (formerly C1orf56), a previously uncharacterized high-risk PD gene. We show that NRG6 encodes a conserved epidermal growth factor-like domain structurally and functionally analogous to neuregulin-1, which is critical for oligodendrocyte development and myelination. These findings redefine the cellular architecture of PD vulnerability and identify neuregulin-like signaling in oligodendrocytes as a potential contributor to non-motor symptoms.
Open AccessRedefining Parkinson's Disease by Dysregulated Genetic Networks in Distinct Cell Types
Parkinson's disease (PD) is classically linked to dopaminergic neuron loss, but emerging evidence suggests broader cellular involvement. Here we show that PD risk variants converge on distinct molecular networks across specific brain cell types, enabling stratification of patients into six subgroups: dopaminergic, oligodendrocyte progenitor cells (O), excitatory (E), dopaminergic/excitatory, dopaminergic/oligodendrocyte and other. While all subgroups exhibit motor symptoms, the E-group individuals also display more severe non-motor symptoms, including dementia, hyposmia, and REM sleep behavior disorder. The O-group individuals exhibit reduced myelin integrity, as demonstrated by diffusion tensor imaging, implicating NRG6 (formerly C1orf56), a previously uncharacterized high-risk PD gene. We show that NRG6 encodes a conserved epidermal growth factor-like domain structurally and functionally analogous to neuregulin-1, which is critical for oligodendrocyte development and myelination. These findings redefine the cellular architecture of PD vulnerability and identify neuregulin-like signaling in oligodendrocytes as a potential contributor to non-motor symptoms.
- Open Access
Common and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene mutational constraints, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes.
Open AccessCommon and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene mutational constraints, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes.
- Open Access
- 9 December 2024
- Published by Springer Nature in Molecular Systems Biology
- Vol. 21 (1) , 1-29
State of the interactomes: an evaluation of molecular networks for generating biological insights
Advancements in genomic and proteomic technologies have powered the creation of large gene and protein networks (“interactomes”) for understanding biological systems. However, the proliferation of interactomes complicates the selection of networks for specific applications. Here, we present a comprehensive evaluation of 45 current human interactomes, encompassing protein-protein interactions as well as gene regulatory, signaling, colocalization, and genetic interaction networks. Our analysis shows that large composite networks such as HumanNet, STRING, and FunCoup are most effective for identifying disease genes, while smaller networks such as DIP, Reactome, and SIGNOR demonstrate stronger performance in interaction prediction. Our study provides a benchmark for interactomes across diverse biological applications and clarifies factors that influence network performance. Furthermore, our evaluation pipeline paves the way for continued assessment of emerging and updated interaction networks in the future.
- 9 December 2024
- Published by Springer Nature in Molecular Systems Biology
- Vol. 21 (1) , 1-29
Open AccessState of the interactomes: an evaluation of molecular networks for generating biological insights
Advancements in genomic and proteomic technologies have powered the creation of large gene and protein networks (“interactomes”) for understanding biological systems. However, the proliferation of interactomes complicates the selection of networks for specific applications. Here, we present a comprehensive evaluation of 45 current human interactomes, encompassing protein-protein interactions as well as gene regulatory, signaling, colocalization, and genetic interaction networks. Our analysis shows that large composite networks such as HumanNet, STRING, and FunCoup are most effective for identifying disease genes, while smaller networks such as DIP, Reactome, and SIGNOR demonstrate stronger performance in interaction prediction. Our study provides a benchmark for interactomes across diverse biological applications and clarifies factors that influence network performance. Furthermore, our evaluation pipeline paves the way for continued assessment of emerging and updated interaction networks in the future.
- Open Access
State of the Interactomes: an evaluation of molecular networks for generating biological insights
Advancements in genomic and proteomic technologies have powered the use of gene and protein networks (“interactomes”) for understanding genotype-phenotype translation. However, the proliferation of interactomes complicates the selection of networks for specific applications. Here, we present a comprehensive evaluation of 46 current human interactomes, encompassing protein-protein interactions as well as gene regulatory, signaling, colocalization, and genetic interaction networks. Our analysis shows that large composite networks such as HumanNet, STRING, and FunCoup are most effective for identifying disease genes, while smaller networks such as DIP and SIGNOR demonstrate strong interaction prediction performance. These findings provide a benchmark for interactomes across diverse network biology applications and clarify factors that influence network performance. Furthermore, our evaluation pipeline paves the way for continued assessment of emerging and updated interaction networks in the future.
Open AccessState of the Interactomes: an evaluation of molecular networks for generating biological insights
Advancements in genomic and proteomic technologies have powered the use of gene and protein networks (“interactomes”) for understanding genotype-phenotype translation. However, the proliferation of interactomes complicates the selection of networks for specific applications. Here, we present a comprehensive evaluation of 46 current human interactomes, encompassing protein-protein interactions as well as gene regulatory, signaling, colocalization, and genetic interaction networks. Our analysis shows that large composite networks such as HumanNet, STRING, and FunCoup are most effective for identifying disease genes, while smaller networks such as DIP and SIGNOR demonstrate strong interaction prediction performance. These findings provide a benchmark for interactomes across diverse network biology applications and clarify factors that influence network performance. Furthermore, our evaluation pipeline paves the way for continued assessment of emerging and updated interaction networks in the future.
- 18 January 2023
- Published by Springer Nature in Nature Protocols
- Vol. 18 (6) , 1745-1759
Mapping the common gene networks that underlie related diseases
A longstanding goal of biomedicine is to understand how alterations in molecular and cellular networks give rise to the spectrum of human diseases. For diseases with shared etiology, understanding the common causes allows for improved diagnosis of each disease, development of new therapies and more comprehensive identification of disease genes. Accordingly, this protocol describes how to evaluate the extent to which two diseases, each characterized by a set of mapped genes, are colocalized in a reference gene interaction network. This procedure uses network propagation to measure the network ‘distance’ between gene sets. For colocalized diseases, the network can be further analyzed to extract common gene communities at progressive granularities. In particular, we show how to: (1) obtain input gene sets and a reference gene interaction network; (2) identify common subnetworks of genes that encompass or are in close proximity to all gene sets; (3) use multiscale community detection to identify systems and pathways represented by each common subnetwork to generate a network colocalized systems map; (4) validate identified genes and systems using a mouse variant database; and (5) visualize and further investigate select genes, interactions and systems for relevance to phenotype(s) of interest. We demonstrate the utility of this approach by identifying shared biological mechanisms underlying autism and congenital heart disease. However, this protocol is general and can be applied to any gene sets attributed to diseases or other phenotypes with suspected joint association. A typical NetColoc run takes less than an hour. Software and documentation are available at https://github.com/ucsd-ccbb/NetColoc.
- 18 January 2023
- Published by Springer Nature in Nature Protocols
- Vol. 18 (6) , 1745-1759
Mapping the common gene networks that underlie related diseases
A longstanding goal of biomedicine is to understand how alterations in molecular and cellular networks give rise to the spectrum of human diseases. For diseases with shared etiology, understanding the common causes allows for improved diagnosis of each disease, development of new therapies and more comprehensive identification of disease genes. Accordingly, this protocol describes how to evaluate the extent to which two diseases, each characterized by a set of mapped genes, are colocalized in a reference gene interaction network. This procedure uses network propagation to measure the network ‘distance’ between gene sets. For colocalized diseases, the network can be further analyzed to extract common gene communities at progressive granularities. In particular, we show how to: (1) obtain input gene sets and a reference gene interaction network; (2) identify common subnetworks of genes that encompass or are in close proximity to all gene sets; (3) use multiscale community detection to identify systems and pathways represented by each common subnetwork to generate a network colocalized systems map; (4) validate identified genes and systems using a mouse variant database; and (5) visualize and further investigate select genes, interactions and systems for relevance to phenotype(s) of interest. We demonstrate the utility of this approach by identifying shared biological mechanisms underlying autism and congenital heart disease. However, this protocol is general and can be applied to any gene sets attributed to diseases or other phenotypes with suspected joint association. A typical NetColoc run takes less than an hour. Software and documentation are available at https://github.com/ucsd-ccbb/NetColoc.